SCH-221510

Last updated
SCH-221510
SCH-221510.svg
Names
IUPAC name
(1S,5R)-8-[Bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
PubChem CID
  • InChI=1S/C28H31NO/c1-20-10-6-8-14-25(20)27(26-15-9-7-11-21(26)2)29-23-16-17-24(29)19-28(30,18-23)22-12-4-3-5-13-22/h3-15,23-24,27,30H,16-19H2,1-2H3/t23-,24+,28?
    Key: LOSJNRBXNQTUNT-XUEDKKMFSA-N
  • CC1=CC=CC=C1C(C2=CC=CC=C2C)N3[C@@H]4CC[C@H]3CC(C4)(C5=CC=CC=C5)O
Properties
C28H31NO
Molar mass 397.562 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

SCH-221510 is an experimental opioid drug. It has potential as an analgesic and as a treatment to addiction of certain drugs.

Contents

Mechanism of action

Most opioid analgesics act through delta, mu, and kappa opioid receptors; however, SCH-221510 is instead an agonist at the nociceptin receptor. [1]

Analgesic effects

Classical opioid analgesics (such as morphine) usually have effects such as constipation, hypoventilation and addiction. [2] However, by acting through a different receptor, SCH-221510 seems to be lacking the undesirable effects of morphine at equianalgesic doses. [1] This suggests that SCH-221510 could be a better opioid than the currently available opioid pain medications, by having less side effects.

Treatment of drug addiction

SCH-221510 might be an option in the treatment of certain drug addictions: it is able to decrease ethanol self-administration [3] and was able to decrease self-administration of remifentanil, a fentanyl analogue, in a study, [4]

References

  1. 1 2 Lin, Ann P.; Ko, Mei-Chuan (2012-10-24). "The Therapeutic Potential of Nociceptin/Orphanin FQ Receptor Agonists as Analgesics without Abuse Liability". ACS Chemical Neuroscience. 4 (2): 214–224. doi:10.1021/cn300124f. ISSN   1948-7193. PMC   3582300 . PMID   23421672.
  2. ↑ Nakatani, Toshihiko (April 2017). "[Opioid Therapy and Management of Side Effects Associated with Opioids]". Gan to Kagaku Ryoho. Cancer & Chemotherapy. 44 (4): 294–297. ISSN   0385-0684. PMID   28428507.
  3. ↑ Flynn, Shawn M.; Epperly, Phillip M.; Davenport, April T.; Cami-Kobeci, Gerta; Husbands, Stephen M.; Ko, Mei-Chuan; Czoty, Paul W. (July 2019) [Published online: 10 April 2019]. "Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys". Neuropsychopharmacology. 44 (8): 1476–1484. doi: 10.1038/s41386-019-0390-z . ISSN   1740-634X. PMC   6784996 . PMID   30970376.
  4. ↑ Sukhtankar, Devki D.; Lagorio, Carla H.; Ko, Mei-Chuan (2014-12-15). "Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats". European Journal of Pharmacology. 745: 182–189. doi:10.1016/j.ejphar.2014.10.029. ISSN   1879-0712. PMC   4259829 . PMID   25446568.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.